产品说明书

Prulifloxacin

Print
Chemical Structure| 123447-62-1 同义名 : NM441;AF 3013
CAS号 : 123447-62-1
货号 : A151816
分子式 : C21H20FN3O6S
纯度 : 98%
分子量 : 461.463
MDL号 : MFCD00864847
存储条件：

粉末 Inert atmosphere,Room Temperature

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 12 mg/mL(26 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：
生物活性
描述 Prulifloxacin is a new fluoroquinolone with indications in the treatment of urinary tract infection and acute exacerbations of chronic bronchitis[3]. Prulifloxacin is the active metabolite of ulifloxacin with a broad in vitro activity spectrum against Gram positive and negative bacteria and among fluoroquinolones has the lowest power of inducing resistance. Prulifloxacin shows a high safety profile: it is the fluoroquinolone with the lowest risk of cardiac arrhythmias for prolongation of the QT interval; the CNS(central nervous system) penetration is negligible; in women prulifloxacin does not affect the lactobacillary component of the vaginal microbiota, lowering the risk of genito-urinary tract infections[4]. In well-designed clinical trials, prulifloxacin 600 mg administered once daily for 10 days in patients with AECB (acute exacerbations of chronic bronchitis) showed good clinical and bacteriological efficacy[5].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT00392574 Acute Gastroenteritis in Adult... 展开 >> Travelers 收起 << Phase 3 Completed - United States, Pennsylvania ... 展开 >> INC Research New Hope, Pennsylvania, United States, 18938 收起 <<
NCT00448422 Acute Bacterial Gastroenteriti... 展开 >>s 收起 << Phase 3 Completed - India ... 展开 >> Goa Medical College Bambolim, Goa, India 收起 <<
NCT02130713 Chronic Bacterial Prostatitis Phase 4 Completed - Italy ... 展开 >> policlinico Umberto I - Department of Gynecological-Obstetrics Sciences and Urological Sciences Roma, Italy, 00161 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.17mL

0.43mL

0.22mL

10.84mL

2.17mL

1.08mL

21.67mL

4.33mL

2.17mL
参考文献

[1]Chen Y, Yang H, et al. Prulifloxacin versus levofloxacin in the treatment of respiratory and urinary tract infections: a multicentre, double-blind, randomized controlled clinical trial. Chemotherapy. 2012;58(3):249-56.

[2]Rafailidis PI, Polyzos KA, et al. Prulifloxacin: a review focusing on its use beyond respiratory and urinary tract infections. Int J Antimicrob Agents. 2011 Apr;37(4):283-90.

[3]Blasi F, Aliberti S, Tarsia P, Santus P, Centanni S, Allegra L. Prulifloxacin: a brief review of its potential in the treatment of acute exacerbation of chronic bronchitis. Int J Chron Obstruct Pulmon Dis. 2007;2(1):27–31

[4]Geddes AM, Klugman KP, Rolinson GN. Introduction: historical perspective and development of amoxicillin/clavulanate. Int J Antimicrob Agents. 2007;30 Suppl 2:S109–S112

[5]Cazzola M, Salvatori E, Dionisio P, Allegra L. Prulifloxacin: a new fluoroquinolone for the treatment of acute exacerbation of chronic bronchitis. Pulm Pharmacol Ther. 2006;19 Suppl 1:30–37